Traditional Chinese Medicine
- 764.026
- +0.289+0.04%
A quick overview: Hong Kong stock market bullish and bearish stock list for October is out! Good performance, china-affiliated brokerage stocks continue to party, haitong sec soars 79%; positive restructuring news boosts chongqing iron with a 45% surge.
The Hang Seng Tech Index has experienced a significant drop this month, with a cumulative decline of over 5%; the Hang Seng Index and the A-share Index have fallen by 3.86% and 3.27% respectively.
Is it the most 'rolled up' in history? The tenth batch of national procurement pharmaceutical catalog is officially announced, with up to 31 companies competing for a single variety.
①This afternoon, the National Pharmaceutical Centralized Procurement Office officially announced the tenth batch of national procurement pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Many industry insiders believe that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A few days ago, a leaked document of the tenth batch of national procurement reporting list circulated within the industry. Today, when reporters verified with the relevant department, they indicated that it is an internal document not for public disclosure, and the formal centralized procurement document will be released publicly in the future; ② Several industry experts have informed reporters that this reporting list does not represent the final procurement list, but the competitive landscape of the tenth batch of national procurement will start with at least seven companies; ③ The competition for the tenth batch of national procurement will be particularly intense.
The central bank has launched two measures at the same time! The reserve requirement ratio is reduced by 0.5 percentage points, and the 7-day reverse repurchase operation interest rate is lowered by 20 basis points.
Starting from September 27, 2024, the reserve requirement ratio for financial institutions is reduced by 0.5 percentage points. After this reduction, the weighted average reserve requirement ratio for financial institutions is approximately 6.6%.
From January to July, the cumulative scale of the national retail pharmacy market reached 299.1 billion yuan, a year-on-year decrease of 3.3%.
The listing of Dapagliflozin Metformin ER tablets will further intensify the competition in the domestic antidiabetic drug market.
Announcement Selection | cspc pharma plans to repurchase up to 5 billion Hong Kong dollars of shares; Sun Insurance: Sunshine Life Insurance premium income from January to August is 66.384 billion yuan
China Railway Signal & Communication Corporation (03969.HK) won a total of approximately 2.9 billion yuan worth of projects from July to August; Tencent (00700.HK) spent 1.002 billion Hong Kong dollars on repurchasing 2.6 million shares on September 19; Alibaba-SW (09988.HK) spent 59.977 million US dollars on repurchasing 5.678 million shares on September 18.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
①The growth rate of total sales revenue of retail pharmacies has slowed down, and the competition continues to intensify. In the first half of this year, major leading chain drugstores found it difficult to increase revenue and profit; ②In the future, the focus of pharmacy competition will shift to product extension and services. According to Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all terminals is expected to decrease to 4.9% in 2024, compared to the decline in 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
① At the 2024 New Investment Conference hosted by Forrester Sullivan, the issue of going global was highly favored by the participants. ② There is a new trend in the global expansion of innovative drugs in our country, such as the number of BDs going global surpassing License-in for the first time in 2023. ③ Some experts at the conference proposed a rational view and called for the need to strengthen internal capabilities, not just rely on enthusiasm.
Hong Kong Stock Opportunity Tracker | Xiaomi's second quarter revenue increased by nearly 30%, with a gross margin of 15.4% for autos; Latest exposure! Duan Yongping increased his holdings of Alibaba and Tencent.
cgn power's revenue in the first half of the year was approximately 39.377 billion yuan, a year-on-year increase of 0.3%; jd.com: as of August 20th, walmart no longer holds shares in the company.
Over 400 pharmaceuticals selected! The preliminary list of the 2024 National Drug Reimbursement List has been published. Experts predict that the threshold for innovative drugs may be lowered.
This year, 440 pharmaceuticals were preliminarily reviewed and included in the drug list for national medical insurance negotiations, with 196 and 244 pharmaceuticals inside and outside the catalog respectively. Many of the applied drugs are innovative drugs that will be launched in June. Several of them have preemptively reduced their prices to increase the probability of successful negotiations. Based on supportive policies, experts predict that the threshold for access to innovative drugs may be lowered this year, and the number of them may increase.
The list of initial review of the national dialogue in 2024 has been announced! Many heavyweight innovative drugs are listed, and almost all CAR-T varieties are gathered. Will there be breakthroughs? | Industry observation
This evening, the National Medical Insurance Bureau announced the list of drugs that passed the preliminary review of the national negotiations this year. The bureau received 626 applications from enterprises, and 440 drugs passed the preliminary review. Several heavy-weight innovative drugs have been approved by the wire or reduced in price, which is considered by the industry as the most important channel for the commercial realization of innovative drugs through medical insurance eligibility. Almost all types of domestic CAR-T are gathered, and experts predict that there may be breakthroughs this year.
Midday Snapshot | Hong Kong stocks rise and fall, Hang Seng index falls nearly 1%; Macau casino stocks rise against the trend, MGM China up more than 5%.
Cryptocurrency spot ETFs plummeted, with Bosera Ethereum, Huaxia Ethereum, and Jiashi Ethereum falling by more than 27%, while Jiashi Bitcoin and Bosera Bitcoin fell nearly 16%.
HK stocks outlook: 15 imported online games have been approved for publication; Xiabuxiabu is expected to experience a mid-term net profit loss compared to the same period last year.
Heytea International expects a net loss of approximately 420-490 million yuan after adjustments in the first half of the year; Techsea International expects a midterm net loss of $4-5 million, a year-on-year shift from profit to loss.
These listed companies have been "crossing the threshold" since July! Institutions conducted group research on csi sws health care index stocks, and here is a list of stocks with the highest number of institutional receptions.
① List of listed companies that have received visits from over 160 institutions since July (see attached figure). Montage Technology, Zhejiang Crystal-Optech, and Espressif Systems are among the top three. ② In the medical and pharmaceutical industry, Lianyi Medical, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., China Resources Boya Bio-pharmaceutical Group, Maiwei Biology-U, and Zhejiang Jolly Pharmaceutical are also "listed".
Baiyunshan: investing 3.2 billion yuan to build Tianhua Park, strengthening the integration of the company's production and logistics resources|Quick announcement reading.
Baiyunshan International Pharmaceutical, a wholly-owned subsidiary of Baiyunshan, plans to invest 3.2 billion yuan in the Tianhua Park project of Guangzhou Baiyunshan Fashion TCM Valley in the Meili Health Industry Park. Prior to this, Hejigong, Mingxing, Hehuang and other enterprises under Baiyunshan, as well as the Guangzhou pharmaceutical logistics project, had settled in the park. The company believes that the construction of the Tianhua Park project is conducive to the integration of resources and development, and strengthens the interaction and cooperation between the company's "Danan Medicine" sector and "Big Business" sector.
Mid-day overview: Hong Kong stocks are consolidating with the Hang Seng Index up nearly 2%; Mainland real estate is booming with Shimao Group up more than 14%.
Network technology rose, JD.com Group rose more than 4%, Meituan, Alibaba, Tencent Holdings, and Kuaishou all rose more than 2%.
Hong Kong's pharmaceutical stocks rebounded today! After a deep adjustment from the beginning of the year until now, can they achieve a bottom-up rebound?
Since 2024, innovative drugs have received a variety of benefits from the policy combination. From multi-dimensional support for speeding up the registration and evaluation of innovative drugs, promoting multi-tiered innovation, and reasonable pricing of new drugs, the policy has moved from 'encouraging large-scale innovation' to 'encouraging high-quality innovation'.
The pilot import of natural ox gallstones has been opened up, and the industry expects the high price to fall.
Today, the website of the National Medical Products Administration published a notice soliciting opinions on the pilot use of imported synthetic musk in the production of Chinese patent medicine, proposed to open up some natural musk imports that meet the requirements.
Pharmaceutical price comparison and the rise of medicinal materials bring a slight chill to the hot traditional chinese medicine industry. | Research series on the traditional chinese medicine industry.
The index of the traditional chinese medicine industry has experienced ups and downs in the past year, with obvious impact from changes in medical insurance policies on market trends. At the same time, the rise in the price of medicinal materials has led to a significant increase in enterprise costs, resulting in significant differentiation in the stock price trends of some traditional chinese medicine companies.